Glycemic variability in inadequately controlled type 1 diabetes and type 2 diabetes on intensive insulin therapy: A cross-sectional, observational study

Diabetes Technology and Therapeutics

Volumn 12, Issue 9, 2010, Pages 695-699

  Greven, Wendela L ^a   Beulens, Joline W J ^a   Biesma, Douwe H ^a   Faiz, Sandra ^a   De Valk, Harold W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; BLOOD GLUCOSE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 77955677620     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0044     Document Type: Article

References (14)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin- dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 1993;329:977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998;352:837-853.
3. Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-1708.
4. Siegelaar SE, Holleman F, Hoekstra JB, Devries JH: Glucose variability; does it matter? Endocr Rev 2010;31:171-182.
5. Rodbard D: Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009;11(Suppl 1):S-55-S-67.
6. Bode BW, Schwartz S, Stubbs HA, Block JE: Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care 2005;28:2361-2366.
7. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR: Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010;53:562-571.
8. McDonnellCM,DonathSM, Vidmar SI,WertherGA, Cameron FJ: A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005;7:253-263.
9. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, Devries JH: Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008;51:183-190.
10. Rodbard D: New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009;11:551-565.
11. Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ, Hovorka R, Salzsieder E: Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009;32:1058-1062.
12. Murata GH, Duckworth WC, Shah JH, Wendel CS, Hoffman RM: Sources of glucose variability in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Clin Endocrinol (Oxf) 2004;60:451-456.
13. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G: Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010;24:79-83.
14. McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B: Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine. Diabetes Technol Ther 2009;11:339-344.